Why Is Apple Stock Not Joining the Broader Market Rally?
The S&P 500 has sprinted 4.92% higher so far in…
Buy
54
VIGL Quote, Financials, Valuation and Earnings
Last price:
$7.95
Seasonality move
:
49.22%
Day range:
$7.94 - $7.95
52-week range:
$1.31 - $7.96
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.70x
Volume:
304K
Avg. volume:
2.5M
1-year change:
77.46%
Market cap:
$371M
Revenue:
--
EPS (TTM):
-$2.05
Analysts' Opinion
-
Consensus RatingVigil Neuroscience has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.52, Vigil Neuroscience has an estimated upside of 19.8% from its current price of $7.95.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $7.95.
Fair Value
-
According to the consensus of 8 analysts, Vigil Neuroscience has 19.8% upside to fair value with a price target of $9.52 per share.
VIGL vs. S&P 500
-
Over the past 5 trading days, Vigil Neuroscience has underperformed the S&P 500 by -2.96% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Vigil Neuroscience does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vigil Neuroscience has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Vigil Neuroscience reported revenues of --.
Earnings Growth
-
Vigil Neuroscience has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Vigil Neuroscience reported earnings per share of -$0.49.
Enterprise value:
283.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-5.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$74.3M | -$89.5M | -$91.7M | -$21.4M | -$23.5M | |
| EBITDA | -$74.2M | -$89.1M | -$91.3M | -$21.3M | -$23.3M | |
| Diluted EPS | -$2.12 | -$2.12 | -$2.05 | -$0.50 | -$0.49 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $170.4M | $172.2M | $106.5M | $90.2M | |
| Total Assets | -- | $172.8M | $192.4M | $125.1M | $107.1M | |
| Current Liabilities | -- | $6.6M | $7.4M | $8.6M | $30.4M | |
| Total Liabilities | -- | $6.6M | $21M | $21.3M | $42M | |
| Total Equity | -- | $166.2M | $171.3M | $103.8M | $65.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$69.2M | -$70.1M | -$53.2M | -$21.9M | -$23.9M | |
| Cash From Investing | -$69.8M | $20.3M | $15.5M | $16.5M | $23.2M | |
| Cash From Financing | $71.3M | $5.9M | $37.6M | $5.2M | $13.3M | |
| Free Cash Flow | -$70.5M | -$70.2M | -$53.5M | -$21.9M | -$24.2M | |
VIGL
Sector
Market Cap
$371M
$33.5M
Price % of 52-Week High
99.87%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
77.46%
-35.33%
Beta (5-Year)
--
0.631
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$7.93
200-day SMA
Buy
Level
$3.23
Bollinger Bands (100)
Buy
Level
1.12 - 6.12
Chaikin Money Flow
Sell
Level
-34.2M
20-day SMA
Buy
Level
$7.90
Relative Strength Index (RSI14)
Buy
Level
88.44
ADX Line
Buy
Level
70.47
Williams %R
Sell
Level
-8.3333
50-day SMA
Buy
Level
$5.05
MACD (12, 26)
Buy
Level
0.75
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
99M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
Stock Forecast FAQ
In the current month, VIGL has received 0 Buy ratings 8 Hold ratings, and 0 Sell ratings. The VIGL average analyst price target in the past 3 months is $9.52.
-
Where Will Vigil Neuroscience Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vigil Neuroscience share price will rise to $9.52 per share over the next 12 months.
-
What Do Analysts Say About Vigil Neuroscience?
Analysts are divided on their view about Vigil Neuroscience share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vigil Neuroscience is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Vigil Neuroscience's Price Target?
The price target for Vigil Neuroscience over the next 1-year time period is forecast to be $9.52 according to 8 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is VIGL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vigil Neuroscience is a Hold. 8 of 8 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of VIGL?
You can purchase shares of Vigil Neuroscience via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vigil Neuroscience shares.
-
What Is The Vigil Neuroscience Share Price Today?
Vigil Neuroscience was last trading at $7.95 per share. This represents the most recent stock quote for Vigil Neuroscience. Yesterday, Vigil Neuroscience closed at $7.95 per share.
-
How To Buy Vigil Neuroscience Stock Online?
In order to purchase Vigil Neuroscience stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Google Stock Double by 2030?
If you bought Alphabet (NASDAQ: GOOGL) when Gmail launched in…
Why Did David Tepper Sell NVIDIA Stock?
In Q1, billionaire David Tepper of Appaloosa Management sold nearly…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 54x
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
49
NKE alert for Jun 28
Nike [NKE] is up 15.29% over the past day.
Buy
81
KTOS alert for Jun 28
Kratos Defense & Security Solutions [KTOS] is up 10.89% over the past day.
Sell
44
GDXU alert for Jun 28
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 10.89% over the past day.
